CAM
BBOT

Cormorant Asset Management’s BridgeBio Oncology BBOT Stock Holding History

Cormorant Asset Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160M Hold
17,878,594
– – 8.04% 2
2025
Q4 		$224M Hold
17,878,594
– – 10.35% 2
2025
Q3 		$207M Buy
17,878,594
+14,969,594
+515% +$156M 14.29% 1
2025
Q2 		$30.9M Hold
2,909,000
– – 2.3% 13
2025
Q1 		$32.9M Hold
2,909,000
– – 2.47% 11
2024
Q4 		$30.5M Hold
2,909,000
– – 1.68% 16
2024
Q3 		$30.4M Hold
2,909,000
– – 1.61% 22
2024
Q2 		$29.7M Hold
2,909,000
– – 1.72% 17
2024
Q1 		$30.3M Buy
+2,909,000
New +$30.1M 1.33% 24

Other funds holding BBOT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Cormorant Asset Management's BBOT Position: Q1 2026 in Review

Cormorant Asset Management held its BridgeBio Oncology (BBOT) position steady in Q1 2026 at 17,878,594 shares worth $160M. The position accounts for 8.04% of the portfolio, ranked #2.

Cormorant Asset Management first reported a position in BBOT in Q1 2024 and has held it in 9 quarters since. The position peaked at $224M in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Cormorant Asset Management held 17,878,594 shares of BridgeBio Oncology worth $160M as of Q1 2026.
  • Cormorant Asset Management left its BridgeBio Oncology share count unchanged in Q1 2026.
  • BridgeBio Oncology made up 8.04% of Cormorant Asset Management's portfolio in Q1 2026, its #2 holding.
  • Cormorant Asset Management first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 9 quarters since.
  • Cormorant Asset Management's BridgeBio Oncology position peaked at $224M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.